Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Stock Information for Avenue Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avenue Therapeutics Inc.

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
Mustang Bio Announces Closing of $4 Million Public Offering
Mustang Bio Announces Pricing of $4 Million Public Offering
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.